Karin M. Hoffmeister
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Karin M. Hoffmeister has a total of 106 co-authors. Here are the top co-authors by number of shared publications:
- Hervé Falet
Translational Glycomics Center, Versiti Blood Research Institute, Milwaukee, WI, United States
7 shared publications Katelyn E. Rosenbalm
Versiti Blood Research Institute, Milwaukee, USA
5 shared publicationsLeonardo Rivadeneyra
Versiti Blood Research Institute, Milwaukee, USA
5 shared publicationsAgata Steenackers
Versiti Blood Research Institute, Milwaukee, USA
3 shared publications- Joseph T. Y. Lau
Department of Molecular & Cellular Biology, Roswell Park Comprehensive Cancer Center, Elm & Carlton Streets, Buffalo, NY 14263, USA
3 shared publications - Leonardo Rivadeneyra
Translational Glycomics Center, Versiti Blood Research Institute, Milwaukee, WI; and
3 shared publications
Latest Publications
- 14 October 2026
- Published by Elsevier in Hematology/Oncology Clinics of North America
Platelet Clearance
- 14 October 2026
- Published by Elsevier in Hematology/Oncology Clinics of North America
Platelet Clearance
- Open Access
- 28 August 2026
- Published by Elsevier in Blood Red Cells & Iron
- Vol. 2 (4)
PACSIN2 deletion impairs transferrin uptake and terminal erythroid maturation in mice
- 28 August 2026
- Published by Elsevier in Blood Red Cells & Iron
- Vol. 2 (4)
Open AccessPACSIN2 deletion impairs transferrin uptake and terminal erythroid maturation in mice
- Open Access
- 7 August 2026
- Published by Springer Nature in Nature Communications
- Vol. 17 (1)
Glycosylation orchestrates megakaryocytic fate of hematopoietic stem cells via Wnt-MUC13 signaling
Hematopoietic stem and progenitor cells (HSPCs) sustain blood production through tightly regulated fate decisions. Disruption of this control underlies disorders such as myelodysplastic syndromes (MDS), myeloproliferative neoplasms (MPN), and inherited thrombocytopenias. While transcriptional and epigenetic regulation of HSPCs is well established, the contribution of glycosylation has remained largely unexplored. Here, we identify the glycosyltransferase B4GALT1 as a central regulator of hematopoiesis that integrates extrinsic niche cues with intrinsic transcriptional programs. B4GALT1 shapes the bone marrow microenvironment by generating complex glycan niches that support HSPC function. However, its deficiency produces oncogenic glycan signatures, disrupts HSPC niche integrity, and induces aberrant expression of Mucin 13 (MUC13). These changes expand stem and progenitor pools, enforce megakaryocyte lineage bias, and activate the Wnt–MUC13/β-catenin signaling axis, a pathway tightly linked to proliferation and malignant transformation. Consequently, B4GALT1 loss uncouples proliferation from self-renewal, altering key regulators of stem cell quiescence, lineage balance, and marrow homeostasis. Our findings define a previously unrecognized glycan-dependent regulatory axis that directs HSPC fate through coordinated transcriptional reprogramming, signaling modulation, and niche remodeling. This work establishes aberrant glycosylation as a driver of hematopoietic dysfunction and highlights B4GALT1 as a potential therapeutic target in stem cell–driven blood disorders.
- 7 August 2026
- Published by Springer Nature in Nature Communications
- Vol. 17 (1)
Open AccessGlycosylation orchestrates megakaryocytic fate of hematopoietic stem cells via Wnt-MUC13 signaling
Hematopoietic stem and progenitor cells (HSPCs) sustain blood production through tightly regulated fate decisions. Disruption of this control underlies disorders such as myelodysplastic syndromes (MDS), myeloproliferative neoplasms (MPN), and inherited thrombocytopenias. While transcriptional and epigenetic regulation of HSPCs is well established, the contribution of glycosylation has remained largely unexplored. Here, we identify the glycosyltransferase B4GALT1 as a central regulator of hematopoiesis that integrates extrinsic niche cues with intrinsic transcriptional programs. B4GALT1 shapes the bone marrow microenvironment by generating complex glycan niches that support HSPC function. However, its deficiency produces oncogenic glycan signatures, disrupts HSPC niche integrity, and induces aberrant expression of Mucin 13 (MUC13). These changes expand stem and progenitor pools, enforce megakaryocyte lineage bias, and activate the Wnt–MUC13/β-catenin signaling axis, a pathway tightly linked to proliferation and malignant transformation. Consequently, B4GALT1 loss uncouples proliferation from self-renewal, altering key regulators of stem cell quiescence, lineage balance, and marrow homeostasis. Our findings define a previously unrecognized glycan-dependent regulatory axis that directs HSPC fate through coordinated transcriptional reprogramming, signaling modulation, and niche remodeling. This work establishes aberrant glycosylation as a driver of hematopoietic dysfunction and highlights B4GALT1 as a potential therapeutic target in stem cell–driven blood disorders.
- Open Access
- 27 May 2026
- Published by American Society of Hematology in Blood Advances
- Vol. 10 (14) , 5045-5057
Nascent Pre-Platelets and B4GALT1 Glycosylation Contribute to 5-FU-induced Bone Marrow Recovery
While megakaryocytes (MKs) are essential for hemostasis, vascular integrity, and hematopoietic stem and progenitor cells (HSPCs) support, their role in bone marrow (BM) recovery has remained underexplored. Here, using a 5-fluorouracil (5-FU) injury model, we identify a transient, intramedullary space enriched in extracellular matrix (ECM) proteins such as perlecan, von Willebrand factor (vWF), and heparanase, and functionally responsive GPIbα⁺ platelet particles (termed preplatelets). During 5-FU-induced injury, this compartment undergoes dynamic changes, and its resolution depends on the presence of functional preplatelets and ECM components. Consistent with this, platelet depletion further delays restoration of the intramedullary space despite preserved MK numbers, supporting a critical local role for nascent platelets during 5-FU-induced injury. Furthermore, mice lacking the β-1,4-galactosyltransferase 1 (B4GALT1) develop persistent thrombocytopenia, exhibit mislocalized and morphologically abnormal MKs, and display expansion of MK-biased HSPCs upon 5-FU injury, collectively leading to delayed hematopoietic recovery and expansion of the BM intramedullary space. Single cell transcriptomic analysis of B4GALT1⁻/⁻ MK-biased HSPCs at steady state further revealed disruption of adhesion, cytoskeletal, and Notch1-associated programs required for proplatelet formation and MK interactions with ECM components. Our findings reveal a previously unrecognized role for locally retained platelet intermediates and identify B4GALT1-dependent glycosylation as a key regulator of megakaryocyte integrity, platelet production and hematopoietic recovery after 5-FU-induced myeloablation.
- 27 May 2026
- Published by American Society of Hematology in Blood Advances
- Vol. 10 (14) , 5045-5057
Open AccessNascent Pre-Platelets and B4GALT1 Glycosylation Contribute to 5-FU-induced Bone Marrow Recovery
While megakaryocytes (MKs) are essential for hemostasis, vascular integrity, and hematopoietic stem and progenitor cells (HSPCs) support, their role in bone marrow (BM) recovery has remained underexplored. Here, using a 5-fluorouracil (5-FU) injury model, we identify a transient, intramedullary space enriched in extracellular matrix (ECM) proteins such as perlecan, von Willebrand factor (vWF), and heparanase, and functionally responsive GPIbα⁺ platelet particles (termed preplatelets). During 5-FU-induced injury, this compartment undergoes dynamic changes, and its resolution depends on the presence of functional preplatelets and ECM components. Consistent with this, platelet depletion further delays restoration of the intramedullary space despite preserved MK numbers, supporting a critical local role for nascent platelets during 5-FU-induced injury. Furthermore, mice lacking the β-1,4-galactosyltransferase 1 (B4GALT1) develop persistent thrombocytopenia, exhibit mislocalized and morphologically abnormal MKs, and display expansion of MK-biased HSPCs upon 5-FU injury, collectively leading to delayed hematopoietic recovery and expansion of the BM intramedullary space. Single cell transcriptomic analysis of B4GALT1⁻/⁻ MK-biased HSPCs at steady state further revealed disruption of adhesion, cytoskeletal, and Notch1-associated programs required for proplatelet formation and MK interactions with ECM components. Our findings reveal a previously unrecognized role for locally retained platelet intermediates and identify B4GALT1-dependent glycosylation as a key regulator of megakaryocyte integrity, platelet production and hematopoietic recovery after 5-FU-induced myeloablation.
- 15 October 2025
- Published by Springer Nature
- p. 337-358
Platelet Glycobiology and Its Impact on Health and Disease
- 15 October 2025
- Published by Springer Nature
- p. 337-358
Platelet Glycobiology and Its Impact on Health and Disease
- Open Access
- 12 September 2025
- Published by American Society of Hematology in Blood Advances
- Vol. 9 (18) , 4656-4660
Platelet glycosylation in myelodysplastic syndromes correlates with disease severity
- 12 September 2025
- Published by American Society of Hematology in Blood Advances
- Vol. 9 (18) , 4656-4660
Open AccessPlatelet glycosylation in myelodysplastic syndromes correlates with disease severity
- Open Access
Glycan-Mediated Mechanosensing Regulates Megakaryocyte-Biased Hematopoietic Stem Cell Subsets
SUMMARY: Definitive hematopoietic stem and progenitor cells (HSPCs) development relies on intrinsic and extrinsic programs to meet homeostatic and stress-related demands. The comprehensive mechanisms governing HSPC’s fate remain poorly understood. Our study identifies B4GALT1, a glycosyltransferase essential for N-glycosylation, as a key modulator of HSPC lineage decisions. We demonstrate that B4GALT1 deficiency disrupts glycosylation patterns within the bone marrow (BM) niche, resulting in oncogenic glycan signatures and altered expression of Mucin13 in HSPCs. Loss of B4GALT1 expands HSPC pools and promotes megakaryocyte priming in HSPCs through transcriptional and chromatin modifications, enhancing the Wnt-Mucin13 axis. Mucin13, an oncogene characterized by aberrant glycosylation, underscores the critical role of B4GALT1 in sustaining BM glycosylation and mechanosensing, thereby regulating HSPC fate through functional, transcriptional, and chromatin dynamics. These observations provide insights into the impact of glycan structures on HSPC function, lineage reprogramming, and malignant transformation.
Open AccessGlycan-Mediated Mechanosensing Regulates Megakaryocyte-Biased Hematopoietic Stem Cell Subsets
SUMMARY: Definitive hematopoietic stem and progenitor cells (HSPCs) development relies on intrinsic and extrinsic programs to meet homeostatic and stress-related demands. The comprehensive mechanisms governing HSPC’s fate remain poorly understood. Our study identifies B4GALT1, a glycosyltransferase essential for N-glycosylation, as a key modulator of HSPC lineage decisions. We demonstrate that B4GALT1 deficiency disrupts glycosylation patterns within the bone marrow (BM) niche, resulting in oncogenic glycan signatures and altered expression of Mucin13 in HSPCs. Loss of B4GALT1 expands HSPC pools and promotes megakaryocyte priming in HSPCs through transcriptional and chromatin modifications, enhancing the Wnt-Mucin13 axis. Mucin13, an oncogene characterized by aberrant glycosylation, underscores the critical role of B4GALT1 in sustaining BM glycosylation and mechanosensing, thereby regulating HSPC fate through functional, transcriptional, and chromatin dynamics. These observations provide insights into the impact of glycan structures on HSPC function, lineage reprogramming, and malignant transformation.
- 27 June 2024
- Published by American Society of Hematology in Blood
- Vol. 143 (26) , 2684-2686
Elevating TPO production up a Notch
- 27 June 2024
- Published by American Society of Hematology in Blood
- Vol. 143 (26) , 2684-2686
Elevating TPO production up a Notch
- Open Access
- 9 August 2023
- Published by American Society of Hematology in Blood Advances
- Vol. 7 (16) , 4278-4290
Characterization of the human platelet N- and O-glycome upon storage using tandem mass spectrometry
Changes in surface glycan determinants, specifically sialic acid loss, determine platelet life span. The gradual loss of stored platelet quality is a complex process that fundamentally involves carbohydrate structures. Here, we applied lipophilic extraction and glycan release protocols to sequentially profile N- and O-linked glycans in freshly isolated and 7-day room temperature–stored platelet concentrates. Analytical methods including matrix assisted laser desorption/ionization time-of-flight mass spectrometry, tandem mass spectrometry, and liquid chromatography were used to obtain structural details of selected glycans and terminal epitopes. The fresh platelet repertoire of surface structures revealed diverse N-glycans, including high mannose structures, complex glycans with polylactosamine repeats, and glycans presenting blood group epitopes. The O-glycan repertoire largely comprised sialylated and fucosylated core-1 and core-2 structures. For both N- and O-linked glycans, we observed a loss in sialylated epitopes with a reciprocal increase in neutral structures as well as increased neuraminidase activity after platelet storage at room temperature. The data indicate that loss of sialylated glycans is associated with diminished platelet quality and untimely removal of platelets after storage.
- 9 August 2023
- Published by American Society of Hematology in Blood Advances
- Vol. 7 (16) , 4278-4290
Open AccessCharacterization of the human platelet N- and O-glycome upon storage using tandem mass spectrometry
Changes in surface glycan determinants, specifically sialic acid loss, determine platelet life span. The gradual loss of stored platelet quality is a complex process that fundamentally involves carbohydrate structures. Here, we applied lipophilic extraction and glycan release protocols to sequentially profile N- and O-linked glycans in freshly isolated and 7-day room temperature–stored platelet concentrates. Analytical methods including matrix assisted laser desorption/ionization time-of-flight mass spectrometry, tandem mass spectrometry, and liquid chromatography were used to obtain structural details of selected glycans and terminal epitopes. The fresh platelet repertoire of surface structures revealed diverse N-glycans, including high mannose structures, complex glycans with polylactosamine repeats, and glycans presenting blood group epitopes. The O-glycan repertoire largely comprised sialylated and fucosylated core-1 and core-2 structures. For both N- and O-linked glycans, we observed a loss in sialylated epitopes with a reciprocal increase in neutral structures as well as increased neuraminidase activity after platelet storage at room temperature. The data indicate that loss of sialylated glycans is associated with diminished platelet quality and untimely removal of platelets after storage.
- 2 June 2022
- Published by Oxford University Press (OUP) in Glycobiology
- Vol. 32 (8) , 701-711
Extracellular ST6GAL1 regulates monocyte–macrophage development and survival
Interaction of immune cells with the systemic environment is necessary for the coordinated development and execution of immune responses. Monocyte-macrophage lineage cells reside at the junction of innate and adaptive immunity. Previously we reported that the sialyltransferase ST6GAL1 in the extracellular milieu modulates B cell development and IgG production, granulocyte production, and attenuates acute airway inflammation to bacterial challenge in mouse models. Here, we report that extracellular ST6GAL1 also elicits profound responses in monocyte-macrophage lineage cells. We show that recombinant ST6GAL1 adheres to subsets of thioglycolate-elicited inflammatory cells in the mouse peritoneum and to cultured human monocyte THP-1 cells. Exposure of the inflammatory cells to recombinant ST6GAL1 elicited wholesale changes in the gene expression profile of primary mouse myeloid cells; most notable was the striking up-regulation of monocyte-macrophage and monocyte-derived dendritic cell development pathway signature genes and transcription factors PU.1, NFκB and their target genes, driving increased monocyte-macrophage population and survival ex vivo. In the cultured human monocyte cells, the essential cell surface receptor of the monocyte-macrophage lineage, the M-CSF receptor (M-CSF-R, Csfr1) was a target of extracellular ST6GAL1 catalytic activity. Extracellular ST6GAL1 activated the M-CSF-R and initiated intracellular signaling events, namely, the nuclear translocation of NFκB subunit p65, and phosphorylation of ERK 1/2 and AKT. The findings implicate extracellular ST6GAL1 in monocyte development by a mechanism initiated at the cell surface and support an emerging paradigm of an extracellular glycan-modifying enzyme as a central regulator coordinating immune hematopoietic cell development and function.
- 2 June 2022
- Published by Oxford University Press (OUP) in Glycobiology
- Vol. 32 (8) , 701-711
Extracellular ST6GAL1 regulates monocyte–macrophage development and survival
Interaction of immune cells with the systemic environment is necessary for the coordinated development and execution of immune responses. Monocyte-macrophage lineage cells reside at the junction of innate and adaptive immunity. Previously we reported that the sialyltransferase ST6GAL1 in the extracellular milieu modulates B cell development and IgG production, granulocyte production, and attenuates acute airway inflammation to bacterial challenge in mouse models. Here, we report that extracellular ST6GAL1 also elicits profound responses in monocyte-macrophage lineage cells. We show that recombinant ST6GAL1 adheres to subsets of thioglycolate-elicited inflammatory cells in the mouse peritoneum and to cultured human monocyte THP-1 cells. Exposure of the inflammatory cells to recombinant ST6GAL1 elicited wholesale changes in the gene expression profile of primary mouse myeloid cells; most notable was the striking up-regulation of monocyte-macrophage and monocyte-derived dendritic cell development pathway signature genes and transcription factors PU.1, NFκB and their target genes, driving increased monocyte-macrophage population and survival ex vivo. In the cultured human monocyte cells, the essential cell surface receptor of the monocyte-macrophage lineage, the M-CSF receptor (M-CSF-R, Csfr1) was a target of extracellular ST6GAL1 catalytic activity. Extracellular ST6GAL1 activated the M-CSF-R and initiated intracellular signaling events, namely, the nuclear translocation of NFκB subunit p65, and phosphorylation of ERK 1/2 and AKT. The findings implicate extracellular ST6GAL1 in monocyte development by a mechanism initiated at the cell surface and support an emerging paradigm of an extracellular glycan-modifying enzyme as a central regulator coordinating immune hematopoietic cell development and function.